Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma
Retrieved on:
Tuesday, June 9, 2020
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, AIDS, Other Science, Health, Clinical medicine, Cancer treatments, Cancer, Lung cancer, Antineoplastic drugs, Breakthrough therapy, Carcinoma, Merck, Pembrolizumab, Merkel-cell carcinoma, Transitional cell carcinoma, Non-small-cell lung carcinoma, KEYNOTE-361, Bladder Cancer, Merck
KEYNOTE-361 (ClinicalTrials.gov, NCT02853305 ) is a randomized, open-label, Phase 3 trial evaluating KEYTRUDA as monotherapy and in combination with chemotherapy versus chemotherapy alone, the current standard of care, for the first-line treatment of advanced or metastatic urothelial carcinoma.
Key Points:
- KEYNOTE-361 (ClinicalTrials.gov, NCT02853305 ) is a randomized, open-label, Phase 3 trial evaluating KEYTRUDA as monotherapy and in combination with chemotherapy versus chemotherapy alone, the current standard of care, for the first-line treatment of advanced or metastatic urothelial carcinoma.
- KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
- KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
- In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in 11% of 370 patients with locally advanced or metastatic urothelial carcinoma.